Yasuhiro Fujiwara

country of citizenship: Japan

educated at: Hiroshima University

occupation: researcher

Series

There is nothing here

Create a new serie

Works

There is nothing here

Create a new work

Articles 177

Date

Title

Authors

2020-02-29

MASTER KEY Project: Powering Clinical Development for Rare Cancers Through a Platform Trial

Hitomi S Okuma, Yasuhiro Fujiwara, Kan Yonemori
2020-03-06

Response to Dabrafenib and Trametinib of a Patient with Metaplastic Breast Carcinoma Harboring a BRAF V600E Mutation

Takuji Seo, Emi Noguchi, Kenji Tamura, Yasuhiro Fujiwara, Kan Yonemori, Akihiko Shimomura
2020-04-16

Taxane-induced sensory peripheral neuropathy is associated with an SCN9A single nucleotide polymorphism in Japanese patients

Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Mayu Yunokawa, Akihiko Shimomura
2020-04-20

BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy

Toshikazu Ushijima, Hitoshi Tsuda, Takayuki Kinoshita, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Akihiko Shimomura
2020-01-23

MiR-1285-5p/TMEM194A axis affects cell proliferation in breast cancer

Takahiro Ochiya, Yasuhiro Fujiwara
2020-06-11

Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma

Kazuki Sudo, Kosei Hasegawa, Keiichi Fujiwara, Tomoyasu Katō, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Akihiko Shimomura, Emi Noguchi
2020-07-28

Rare cancers in Japan: definition, clinical features and future perspectives

Yasuhiro Fujiwara
2020-07-23

HER3 protein expression as a risk factor for post-operative recurrence in patients with early-stage adenocarcinoma and adenosquamous carcinoma of the cervix

Tomoyasu Katō, Mitsuya Ishikawa, Yasuhiro Fujiwara, Kan Yonemori, Hitomi S Okuma, Kenji Tamura, Akihiko Shimomura, Tatsunori Shimoi, Emi Noguchi
2020-09-21

Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan

Emi Noguchi, Takuji Okusaka, Yasuhiro Fujiwara, Kan Yonemori, Seiko Bun
2020-09-23

Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging

Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Tatsunori Shimoi
2020-10-07

Neoadjuvant chemotherapy promotes the expression of HER3 in patients with ovarian cancer

Tomoyasu Katō, Mitsuya Ishikawa, Yasuhiro Fujiwara, Kan Yonemori, Hitomi S Okuma, Kenji Tamura, Akihiko Shimomura, Tatsunori Shimoi, Emi Noguchi
2020-12-31

Regulatory and Operational Challenges in Conducting Asian International Academic Trial for Expanding the Indications of Cancer Drugs

Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Emi Noguchi
2019-04-02

Feasibility and utility of a panel testing for 114 cancer-associated genes in a clinical setting: A hospital-based study

Yutaka Fujiwara, Akihiko Shimomura, Takafumi Koyama, Noriko Motoi, Akiko Miyagi-Maeshima, Taiki Hashimoto, Nobuyoshi Hiraoka, Kenji Tamura, Takashi Kohno, Atsushi Ochiai, Hiroshi Yoshida, Yasuhiro Fujiwara, Kan Yonemori
2019-10-01

[Ifosfamide and Paclitaxel for Recurrent or Metastatic Uterine Carcinosarcoma]

Tomoyasu Katō, Mitsuya Ishikawa, Yasuhiro Fujiwara, Kan Yonemori, Hitomi S Okuma, Kenji Tamura, Akihiko Shimomura, Emi Noguchi
2019-01-28

A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes

Akihiko Shimomura, Norikazu Masuda, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura
2019-02-01

The Incidence of Nonmalignant Diseases among Patients with Suspected Carcinoma of Unknown Primary Site

Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Mayu Yunokawa, Makoto Kodaira, Akihiko Shimomura, Tatsunori Shimoi, Emi Noguchi
2019-02-08

Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population

Akihiko Shimomura, Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Tatsunori Shimoi, Emi Noguchi, Hitomi S Okuma
2019-02-12

A multi-national, randomised, open-label, parallel, phase III non-inferiority study comparing NK105 and paclitaxel in metastatic or recurrent breast cancer patients

Junichiro Watanabe, Hiroji Iwata, Katsumasa Kuroi, Yasuhiro Fujiwara
2019-12-10

CYP2D6 Genotype-Guided Tamoxifen Dosing in Hormone Receptor-Positive Metastatic Breast Cancer (TARGET-1): A Randomized, Open-Label, Phase II Study

Michiaki Kubo, Shigehira Saji, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura
2019-09-01

Expectations of and recommendations for a cancer survivorship guideline in Japan: a literature review of guidelines for cancer survivorship

Ryo Okubo, Yoichi Shimizu, Shoichiro Tsugane, Yutaka Matsuoka, Yasuhiro Fujiwara
2019-04-24

Applications of MALDI mass spectrometry imaging for pharmacokinetic studies during drug development

Mitsuhiro Hayashi, Yasuhiro Fujiwara, Hiroaki Aikawa, Masanobu Nishidate, Akinobu Hamada
2019-05-18

Bone marrow examination in patients with Ewing sarcoma/peripheral primitive neuroectodermal tumor without metastasis based on 18F-fluorodeoxyglucose positron emission tomography/computed tomography

Akihiko Shimomura, Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Hitomi S Okuma, Kenji Tamura, Mayu Yunokawa, Makoto Kodaira, Tatsunori Shimoi, Emi Noguchi
2019-05-23

Have We Found the Key to Unravel Treatment Development Lags for Rare Cancers?: MASTER KEY Project

Yasuhiro Fujiwara, Hitomi S Okuma
2019-08-02

Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy

Akihiko Shimomura, Norikazu Masuda, Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura
2019-04-29

A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines

Yasuhiro Fujiwara, Kan Yonemori, Hitomi S Okuma, Kenji Tamura
2018-04-03

Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor

Tatsunori Shimoi, Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Akihiko Shimomura, Emi Noguchi, Seiko Bun
2018-04-06

Distribution of erlotinib in rash and normal skin in cancer patients receiving erlotinib visualized by matrix assisted laser desorption/ionization mass spectrometry imaging

Mitsuhiro Hayashi, Naomi Kiyota, Yasuhiro Fujiwara, Hiroaki Aikawa, Akinobu Hamada
2018-06-05

Efficacy of capecitabine in patients with locally advanced or metastatic breast cancer with or without prior treatment with fluoropyrimidine: a retrospective study

Sakura Iizumi, Akihiko Shimomura, Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Kenji Tamura, Tatsunori Shimoi, Emi Noguchi
2018-07-28

PIK3CA mutation profiling in patients with breast cancer, using a highly sensitive detection system

Tatsunori Shimoi, Tadaaki Nishikawa, Emi Noguchi, Mayu Yunokawa, Kenji Tamura, Takayuki Kinoshita, Chikako Shimizu, Yasuhiro Fujiwara, Kan Yonemori, Akihiko Shimomura
2018-12-11

Invasive breast cancers in adolescent and young adult women show more aggressive immunohistochemical and clinical features than those in women aged 40-44 years

Hitoshi Tsuda, Takayuki Kinoshita, Takashi Hojo, Chikako Shimizu, Yasuhiro Fujiwara, Kenji Tamura, Nobuyoshi Hiraoka
2018-07-23

Trastuzumab emtansine plus pertuzumab in Japanese patients with HER2-positive metastatic breast cancer: a phase Ib study

Hiroji Iwata, Yasuhiro Fujiwara, Kenji Tamura, Emi Noguchi
2018-12-04

Exploration of germline variants responsible for adverse events of crizotinib in anaplastic lymphoma kinase-positive non-small cell lung cancer by target-gene panel sequencing

Yusuke Okuma, Takamasa Hotta, Yasuhiro Fujiwara, Tatsuhiro Shibata, Fumie Hosoda, Hiromi Nakamura

Human - wd:Q99517112

Welcome to Inventaire

the library of your friends and communities

learn more